Abacus Medicine Pharma Services (AMPS) and Luye Pharma Group are proud to announce the signing of an exclusive distribution contract to make Lurbinectedin available to small cell lung cancer patients in Hong Kong via the Named Patient Program (NPP).
Lurbinectedin is indicated for the treatment of adult patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy.
This indication is approved by the US Food and Drug Administration (FDA) under accelerated approval based on overall response rate and duration of response in an open-label, monotherapy clinical trial.
The agreement provides AMPS with exclusive distribution rights for Lurbinectedin to the oncology community in Hong Kong.
William Van, General Manager, Abacus Medicine Pharma Services Asia Limited explains: “We have been developing an excellent relationship with Luye Pharma over the past two years and this NPP partnership is an exciting project to show both the developments taking place within the Chinese pharmaceutical industry and also the development of Abacus Medicine Pharma Services Asia Limited as a recognised pharma services company within the APAC region.”
Continuing, Andy Siow, APAC Regional Director of Luye Pharma (International) explains, “The development of Lurbinectedin is a key milestone in the history of SCLC and we are delighted to partner with Abacus Medicine Pharma Services to make Lurbinectedin accessible to the patients in Hong Kong via this NPP. This represents a significant development of the Luye Pharma oncology portfolio in the region.”